Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
The Health Resources & Services Administration has unveiled its formal plans for a revised version of its contentious 340B Rebate Model Pilot Program, a test run in which statutory upfront disc | A notice from the Health Resources & Services Administration sidelines covered entities' attestations of substantial administrative burden and sets the mulligan program into motion, targeting a Jan. 1 start and 25 potentially eligible products.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

HRSA unveils revised 340B rebate pilot letting drugmakers deny rebates for some drugs.

After years of investigation, the outgoing chairman of the Senate Health, Education, Labor and Pensions Committee has released…

An appellate court panel ruled Tuesday that drug manufacturers may not impose 340B rebates without approval from the U.S.…

The Centers for Medicare and Medicaid Services’ recent proposal to overhaul Medicare’s reimbursement rates for 340B drugs will be…

Outpatient drug purchases under the 340B Drug Pricing Program crossed the $100 billion mark across 2025, a roughly 23% increase…

The Centers for Medicare and Medicaid Services laid the groundwork Tuesday afternoon for another provider tax pullback outlined…